Self‐Adaptive Nanoregulator to Mitigate Dynamic Immune Evasion of Pancreatic Cancer
Advanced Materials · 2023
DOI: 10.1002/adma.202305798 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2023. Verfasst von Jiaxing Pan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 2000092, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Lingang Laboratory.
Abstract (Originalsprache)
The advance of immunotherapy has shifted the paradigm of cancer management in clinics. Nevertheless, a considerable subset of pancreatic ductal adenocarcinoma (PDAC) patients marginally respond to current immunotherapy due to the occurrence of dynamic immune evasion arising from intrinsic and therapeutic stress. In this investigation, the pivotal role of pancreatic cancer‐associated fibroblast (CAF)‐induced fibrosis and tumor cell‐mediated T‐cell exhaustion in driving the dynamic immune evasion is identified. Building upon this discovery, the authors herein engineer a novel peptide‐drug conjugate (PDC)‐based self‐adaptive nanoregulator for mitigating dynamic immune evasion of PDAC. The resulting nanoregulator can perform a two‐stage morphology transformation from spherical micelle to nanofiber, and subsequently from nanofiber to spherical nanoparticles. Such kind of nanostructure design can facilitate differentialized delivery of CAF inhibitor in the extracellular matrix for intervening CAF‐mediated tumor fibrosis, and indoleamine 2,3‐dioxygenase 1 inhibitor to tumor cells for relieving IDO1‐kynurenine axis‐induced T‐cell exhaustion. Antitumor study with the self‐adaptive nanoregulator elicited persistent antitumor immunity and remarkable antitumor performance in both Panc02 and KPC tumor models in vivo. Taken together, the PDC‐based self‐adaptive nanoregulator may provide a novel avenue for enhanced PDAC immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 2000092, China.
- Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
- Department of Gastroenterology, Huadong Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China.
- School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200241, China.
ORCID-Profile: Haijun Yu
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Lingang Laboratory
- China National Postdoctoral Program for Innovative Talents
- Shanghai Post-Doctoral Excellence Program
- China Postdoctoral Science Foundation
Zitieren
APA
Pan, J., Lai, Y., Zhang, S., Zhang, H., Shan, Y., Huang, L., Wang, F., Yu, H., Xu, L., & Xu, Z. (2023). Self‐Adaptive Nanoregulator to Mitigate Dynamic Immune Evasion of Pancreatic Cancer. Advanced Materials. https://doi.org/10.1002/adma.202305798
Vancouver
Pan J, Lai Y, Zhang S, Zhang H, Shan Y, Huang L, et al. Self‐Adaptive Nanoregulator to Mitigate Dynamic Immune Evasion of Pancreatic Cancer. Advanced Materials. 2023. doi:10.1002/adma.202305798
BibTeX
@article{Pan2023,
author = {Pan, Jiaxing and Lai, Yi and Zhang, Shunan and Zhang, Huijuan and Shan, Yiming and Huang, Lujia and Wang, Feng and Yu, Haijun and Xu, Leiming and Xu, Zhiai},
title = {Self‐Adaptive Nanoregulator to Mitigate Dynamic Immune Evasion of Pancreatic Cancer},
journal = {Advanced Materials},
year = {2023},
doi = {10.1002/adma.202305798}
}
EUVIMED